Get the Stockscreener App
206.94
0.52%
-0.915
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $206.94, with a volume of 1.64M.
It is down -0.52% in the last 24 hours and up +0.15% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$207.86
Open:
$206.86
24h Volume:
1.64M
Relative Volume:
0.24
Market Cap:
$365.58B
Revenue:
$62.82B
Net Income/Loss:
$3.60B
P/E Ratio:
102.07
EPS:
2.0274
Net Cash Flow:
$19.98B
1W Performance:
+0.85%
1M Performance:
+0.15%
6M Performance:
-10.98%
1Y Performance:
+9.99%
1-Day Range:
$204.30
$209.41
1-Week Range:
$200.02
$211.32
52-Week Range:
$176.57
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
206.92 | 367.25B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,005.94 | 882.71B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
229.22 | 539.84B | 96.36B | 21.04B | 17.80B | 8.6488 |
AZN
Astrazeneca Plc
|
185.83 | 286.19B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
149.13 | 282.70B | 54.66B | 13.58B | 16.05B | 7.0171 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
AbbVie stock (US00287Y1091): Q1 earnings beat and guidance raise drive 3.1% gain - AD HOC NEWS
AbbVie stock (US00287Y1091): Rises 3.3% on 2026 outlook and AGM results - AD HOC NEWS
The Zacks Analyst Blog NVIDIA, Mastercard, AbbVie, Waterstone and Precipio - Zacks Investment Research
A Look At AbbVie (ABBV) Valuation After New Immunology Data And Upgraded 2026 Earnings Outlook - Yahoo Finance
AbbVie Inc. 8-K SEC Filing May 2026: Common Stock and Senior Notes Registered on NYSE - Minichart
AbbVie Inc. (ABBV) Announces Results of 2026 Annual Meeting of S - GuruFocus
AbbVie Shareholders Back Directors, Maintain Governance Structure - TipRanks
AbbVie Inc (ABBV) Stock Up 3.1% and Still Undervalued -- GF Score: 86/100 - GuruFocus
[Form 4] AbbVie Inc. Insider Trading Activity - Stock Titan
[8-K] AbbVie Inc. Reports Material Event - Stock Titan
Why AbbVie Inc. (ABBV) is One of the Best Healthcare Stocks to Buy for the Long Term - Insider Monkey
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
Top Stock Reports for NVIDIA, Mastercard & AbbVie - Yahoo Finance Singapore
3 reasons to buy AbbVie stock (ABBV) like there's no tomorrow - MSN
AbbVie rises 3.3% as upbeat 2026 outlook and fresh analyst optimism lift sentiment - Quiver Quantitative
3 Reasons to Buy AbbVie Stock (ABBV) Like There's No Tomorrow - The Motley Fool
AbbVie’s Growth Engine Is Firing On All Cylinders (NYSE:ABBV) - Seeking Alpha
AbbVie Stock Deserves A Higher Multiple (NYSE:ABBV) - Seeking Alpha
A Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried? - The Motley Fool
A Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried? - The Motley Fool
United Financial Planning Group LLC's AbbVie Inc(ABBV) Holding History - GuruFocus
Enanta Pharma Q2 loss narrows on higher AbbVie royalties, lower costs - TradingView
AbbVie shares consolidate as technicals point to continued selling pressure: weekly report - Traders Union
AbbVie Stock: Q1, Skyrizi Delivers, Here's What Skeptics Are Missing (NYSE:ABBV) - Seeking Alpha
AbbVie Stock: Is Wall Street Bullish or Bearish? - Barchart.com
ABBV Stock Price, Quote & Chart | ABBVIE INC (NYSE:ABBV) - ChartMill
AbbVie Inc. stock (US00287Y1091): Post-Humira growth and raised 2026 guidance - AD HOC NEWS
AbbVie Q1 earnings loom: Buy or sell the stock ahead of results? - MSN
AbbVie Stock: The Post-Humira Transition Is Working and the Road to $311 - TIKR.com
CFO CAPITAL MANAGEMENT LLC's AbbVie Inc(ABBV) Holding History - GuruFocus
Goldman Sachs Large Cap Equity Fund's AbbVie Inc(ABBV) Holding History - GuruFocus
Total operating expenses of AbbVie, Inc. CDR (CAD Hedged) – TSX:ABBV - TradingView
AbbVie Touts Record Sales and Pipeline Momentum at Annual Meeting - Yahoo Finance
Is It Too Late To Consider AbbVie (ABBV) After Its Recent Share Price Pullback? - Yahoo Finance
AbbVie Inc. stock (US00287Y1091): Q1 2026 sales surge on immunology and aesthetics growth - AD HOC NEWS
Best Pharmaceutical Stocks for 2026 and How to Invest - The Motley Fool
AbbVie (NYSE: ABBV) grows Q1 2026 sales while boosting R&D and deals - Stock Titan
AbbVie (ABBV), adMare BioInnovations Name RIME Therapeutics as Biotech Innovators Award Winner - Insider Monkey
AbbVie Stock Beats Q1 Estimates as Skyrizi Hits $4.5B in a Single Quarter - TIKR.com
AbbVie Inc. stock underperforms Thursday when compared to competitors - MarketWatch
AbbVie Delivers Strong Q1 Earnings Beyond Humira. This Dividend King Still Shines. - Yahoo Finance
Does Strong Q1 Results And SKYRIZI Expansion Reshape The Bull Case For AbbVie (ABBV)? - Yahoo Finance
Safer Dividend King to Buy Now: AbbVie or Johnson & Johnson? - The Motley Fool
Number of shareholders of AbbVie, Inc. CDR (CAD Hedged) – NEO:ABBV - TradingView
AbbVie Announces $1.4B Manufacturing Campus in Durham, NC | 2026News and Statistics - IndexBox
AbbVie to Present at Bank of America Securities Healthcare Conference on May 6, 2026 - geneonline.com
AbbVie to Present at the Bank of America Securities Healthcare Conference - marketscreener.com
5 Must-Read Analyst Questions From AbbVie’s Q1 Earnings Call - The Globe and Mail
Is trending stock AbbVie Inc. (ABBV) a buy now? - MSN
Glenwood Academy students, AbbVie scientists team up for science fair projects - The Lansing Journal
AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases at 2026 Digestive Disease Week - Investing News Network
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.37%
0.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):